Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.009
Neutral
RSI(14)
72.145
Buy
STOCH(KDJ)(9,3,3)
60.073
Buy
ATR(14)
0.017
Low Volatility
CCI(14)
340.613
Overbought
Williams %R
20.000
Overbought
TRIX(12,20)
0.021
Sell
StochRSI(14)
100.000
Buy
Search
Amicus Therapeutics Inc
FOLDAdd to Watchlist
14.490USD
0.0000.00%
Close 05/08, 16:00（ET）Quotes delayed by 15 min
4.55BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Amicus Therapeutics Inc
Currency: USD Updated: 2026-04-24Key Insights
Amicus Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 67 out of 389 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 15.50.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Amicus Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Amicus Therapeutics Inc Highlights
StrengthsRisks
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 58.81% year-on-year.
Undervalued
The company’s latest PE is -164.81, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 326.88M shares, decreasing 6.31% quarter-over-quarter.
Held by Joel Greenblatt
Star Investor Joel Greenblatt holds 139.55K shares of this stock.
Analyst Rating
Based on
0
analysts
--
Current Rating
16.250
Target Price
+12.15%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-04-24Its latest quarterly revenue reached 185.21M, representing a year-over-year increase of 23.72%, while its net profit experienced a year-over-year increase of 88.53%.
Score
Financials
7.04
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
10.00
Operational Efficiency
10.00
Growth Potential
9.46
Shareholder Returns
7.60
Amicus Therapeutics Inc's Company Valuation
Currency: USD Updated: 2026-04-24The current valuation score of Amicus Therapeutics Inc is 7.84, ranking 76 out of 389 in the Biotechnology & Medical Research industry. Its current P/E ratio is -164.81, which is -91.91% below the recent high of -13.33 and -95.68% above the recent low of -322.49.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 67/389
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-04-24The current earnings forecast score of Amicus Therapeutics Inc is 6.25, ranking 334 out of 389 in the Biotechnology & Medical Research industry. The average price target is 16.00, with a high of 22.00 and a low of 11.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
No Data
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-04-24The current price momentum score of Amicus Therapeutics Inc is 4.74, ranking 344 out of 389 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 14.52 and the support level at 14.43, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
14.466
Buy
MA10
14.462
Buy
MA20
14.456
Buy
MA50
14.400
Buy
MA100
13.768
Buy
MA200
10.839
Buy
Institutional Confidence
Currency: USD Updated: 2026-04-24The latest institutional shareholding proportion is 103.70%, representing a quarter-over-quarter decrease of 5.05%. The largest institutional shareholder is The Vanguard, holding a total of 29.29M shares, representing 9.33% of shares outstanding, with 0.96% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-04-24Amicus Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
Score
Beta vs S&P 500 index
0.45
VaR
+4.47%
240-Day Maximum Drawdown
+14.42%
240-Day Volatility
+45.81%
Return
Best Daily Return
60 days
+0.35%
120 days
+30.21%
5 years
+30.21%
Worst Daily Return
60 days
-0.14%
120 days
-3.16%
5 years
-17.18%
Sharpe Ratio
60 days
+3.30
120 days
+2.39
5 years
+0.44
Risk Assessment
Maximum Drawdown
240 days
+14.42%
3 years
+61.16%
5 years
+61.16%
Return-to-Drawdown Ratio
240 days
+9.87
3 years
+0.07
5 years
+0.21
Skewness
240 days
+5.49
3 years
+2.01
5 years
+0.97
Volatility
Realised Volatility
240 days
+45.81%
5 years
+48.91%
Standardised True Range
240 days
+1.53%
5 years
+2.81%
Downside Risk-Adjusted Return
120 days
+979.94%
240 days
+979.94%
Maximum Daily Upside Volatility
60 days
+1.69%
Maximum Daily Downside Volatility
60 days
+1.35%
Liquidity
Average Turnover Rate
60 days
+1.48%
120 days
+1.44%
5 years
--
Turnover Deviation
20 days
+26.69%
60 days
+42.46%
120 days
+38.28%
Peer Comparison
Biotechnology & Medical Research
Amicus Therapeutics Inc
FOLD
7.08 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.76 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AnaptysBio Inc
ANAB
8.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
